Group items tagged

"In some cases, cheaper types of fish were substituted for expensive species. In others, fish that consumers have been urged to avoid because stocks are depleted, putting the species or a fishery at risk, was identified as a type of fish that is not threatened. Although such mislabeling violates laws protecting consumers, it is hard to detect. Some of the findings present public health concerns. Thirteen types of fish, including tilapia and tilefish, were falsely identified as red snapper. Tilefish contains such high mercury levels that the federal Food and Drug Administration advises women who are pregnant or nursing and young children not to eat it."

"Science 25 November 2011: Vol. 334 no. 6059 pp. 1052-1053 DOI: 10.1126/science.334.6059.1052 * News Focus Adaptation to Climate Change Adaptation to Climate Change Time to Adapt to a Warming World, But Where's the Science? 1. Richard A. Kerr With dangerous global warming seemingly inevitable, users of climate information-from water utilities to international aid workers-are turning to climate scientists for guidance. But usable knowledge is in short supply. Figure View larger version: * In this page * In a new window Adapt to that. Climate will change, but decision-makers want to know how, where, and when. "CREDIT: KOOS VAN DER LENDE/NEWSCOM" DENVER, COLORADO-The people who brought us the bad news about climate change are making an effort to help us figure out what to do about it. As climate scientists have shown, continuing to spew greenhouse gases into the atmosphere will surely bring sweeping changes to the world-changes that humans will find it difficult or impossible to adapt to. But beyond general warnings, there is another sort of vital climate research to be done, speakers told 1800 attendees at a meeting here last month. And so far, they warned, researchers have delivered precious little of the essential new science. At the meeting, subtitled "Climate Research in Service to Society,"* the new buzzword was "actionable": actionable science, actionable information, actionable knowledge. "There's an urgent need for actionable climate information based on sound science," said Ghassem Asrar, director of the World Climate Research Programme, the meeting's organizer based in Geneva, Switzerland. What's needed is not simply data but processed information that an engineer sizing a storm-water pipe to serve for the next 50 years or a farmer in Uganda considering irrigating his fields can use to make better decisions in a warming world. Researchers preparing for the next international climate assessment, due in 2013, delive

Northeast - Red Tide/Shellfish Closure Extension Through December 31, 2011 At the request of the U.S. Food and Drug Administration, NOAA Fisheries Service has extended the temporary paralytic shellfish poisoning (PSP) closure through December 31, 2011, due to the presence of high levels of the toxin that causes PSP. See a chart of the closure area. NOAA Fisheries Service may terminate the emergency regulations at an earlier date by publishing a notice of termination in the Federal Register if information becomes available indicating such action is warranted.

As the U.S. Food and Drug Administration (FDA) considers approving a genetically modified (GM) Atlantic salmon (Salmo salar), it faces fundamental questions of risk analysis and impact assessment. The GM salmon-whose genome contains an inserted growth gene from Pacific chinook salmon (Oncorhynchus tshawytscha) and a switch-on gene from ocean pout (Zoarces americanus)-would be the first transgenic animal approved for human consumption in the United States (1, 2). But the mechanism for its approval, FDA's new animal drug application (NADA) process (2), narrowly examines only the risks of each GM salmon compared with a non-GM salmon (2, 3). This approach fails to acknowledge that the new product's attributes may affect total production and consumption of salmon. This potentially excludes major human health and environmental impacts, both benefits and risks. Regulators need to consider the full scope of such impacts in risk analyses to avoid unintended consequences (4), yet FDA does not consider ancillary benefits and risks from salmon market expansion (2, 3), a result of what may be an overly narrow interpretation of statutes.